Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Scorpius HoldingsSCPX EV-to-EBIT is -0.46 as of Aug. 02, 2026. The stock has 7 warning signs investors should review. Among 382 Biotechnology companies, Scorpius Holdings ranks worse than 261779.84% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Scorpius Holdings's Enterprise Value for the quarter that ended in Sep. 2025 was $12.54 Mil.
Scorpius Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scorpius Holdings EV-to-EBIT Related Terms
Scorpius Holdings EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Scorpius Holdings's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Scorpius Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Scorpius Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Scorpius Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Scorpius Holdings's EV-to-EBIT falls into.
Scorpius Holdings's current Enterprise Value is $11.90 Mil.
Scorpius Holdings's EBIT for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-25.84 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Scorpius Holdings (SCPX) has a EV-to-EBIT of -0.46 as of Aug. 02, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Scorpius Holdings and its competitors. According to the industry distribution chart, Scorpius Holdings ranks #999999 out of 382 companies in the Biotechnology industry.
Is Scorpius Holdings' EV-to-EBIT too high?
Scorpius Holdings' current EV-to-EBIT is -0.46. Based on the distribution chart, Scorpius Holdings ranks #999999 out of 382 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Scorpius Holdings' EV-to-EBIT compare to WINT and IOBTQ?
According to the Biotechnology industry distribution chart, Scorpius Holdings ranks #999999 out of 382 companies for EV-to-EBIT. This places Scorpius Holdings in the lower half of its industry. The industry median EV-to-EBIT is 12.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 12.56, based on 382 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Scorpius Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 12.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Scorpius Holdings's current EV-to-EBIT is -0.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scorpius Holdings stock overvalued right now?
Based on GuruFocus' analysis, Scorpius Holdings (SCPX) is currently considered Possible Value Trap. The stock's GF Value™ is $0.14, compared to a current price of $0.00 — trading 99.6% below its estimated fair value. The current EV-to-EBIT is -0.46. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Scorpius Holdings (SCPX), the current EV-to-EBIT is -0.46 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Scorpius Holdings Inc is an integrated contract development and manufacturing organization (CDMO) focused on rapidly advancing biologic and cell therapy programs to the clinic and beyond. It offers a broad array of analytical testing, process development, and manufacturing services to pharmaceutical and biotech companies at its state of the art facilities.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SCPX has been successfully added to your 
